In The Lancet, Jes Lindholt and Rikke Søgaard¹ report the Viborg Vascular (VIVA) trial in which 50 156 Danish men aged 65–74 years were randomly allocated to combined screening for abdominal aortic aneurysm, peripheral arterial disease, and systemic hypertension or to no screening. After a median follow-up of 4·4 years (IQR 3·9–4·8), screening and subsequent intervention reduced absolute risk of overall mortality by 0·006 (95% CI 0·001–0·011), with a number needed to invite (NNI) to screening to save one life of 169 (89–1811).

中文翻译：

---

基于人群的血管疾病筛查

在柳叶刀，赫苏斯Lindholt和RIKKESøgaard ^1份报告中，50种的156人的丹麦65-74岁，随机分配给联合筛查腹主动脉瘤，外周动脉疾病的维堡血管（VIVA）试验中，和全身性高血压或无筛选。在平均随访4·4年（IQR 3·9–4·8）后，筛查和随后的干预措施使总死亡率的绝对风险降低了0·006（95％CI 0·001–0·011），其中需要邀请（NNI）参加筛查的人数，以挽救169人的生命（89-1811）。